Pharmaceutical Group Looking For Participants
The Bristol-Myers Squibb Sanofi-Synthelabo Partnership is screening men and women 18 years of age or older for possible participation in a research study evaluating the safety and effectiveness of an approved medication for lowering high blood pressure.
In traditional societies where people remain lean and physically active through life, blood pressure does not usually rise with age. In developed countries such as the United States, however, blood pressure nearly always rises with advancing age as body fat increases, activity declines, and arteries become stiff and narrowed by accumulating plaque. There are now numerous effective and safe medications that can drastically reduce the risks associated with high blood pressure.
According to the National Heart, Lung, and Blood Institute (NHLBI), about 50 million people in the United States have high blood pressure. High blood pressure is not controlled in two out of three people who have it, and many people with high blood pressure require 2 or more medicines to control it. Uncontrolled high blood pressure may lead to heart problems, damage to the kidneys, and stroke.
In general, for patients with high blood pressure, the NHLBI guidelines advise physicians to lower blood pressure to less than 140/90 mm Hg. However, for patients with diabetes or chronic kidney disease, the guidelines advise lowering blood pressure to less than 130/80 mm, Hg.
A normal blood pressure is less than 120/80 mm Hg. Blood pressure can rise during physical exertion, anger or stress, and then return to normal levels. A diagnosis of high blood pressure is made if blood pressure remains higher than normal over extended periods of time.
New research is being conducted to evaluate the safety and effectiveness of an approved medication for the treatment of high blood pressure. Qualified participants will receive study-related exams, lab tests, and study medication at no charge. Potential study volunteers can call 1-888-41-HEART (1-888-414-3278) for an initial prescreening and additional information.